6-ketoprostaglandin-f1-alpha has been researched along with Nephritis* in 5 studies
1 review(s) available for 6-ketoprostaglandin-f1-alpha and Nephritis
Article | Year |
---|---|
Present status of nephrology in China.
Topics: 6-Ketoprostaglandin F1 alpha; China; Drugs, Chinese Herbal; Erythropoietin; Humans; Kidney; Nephritis; Nephrology | 1995 |
4 other study(ies) available for 6-ketoprostaglandin-f1-alpha and Nephritis
Article | Year |
---|---|
Studies on the antinephritic effect of plant components (4): Reduction of protein excretion by berberine and coptisine in rats with original-type anti-GBM nephritis.
The present study was conducted to investigate the antinephritic effects of berberine and coptisine, which are contained in Coptidis rhizoma, on original-type anti-GBM nephritis in rats. Berberine and coptisine at the doses of 0.5, 1.0 and 5.0 mg/kg/day, i.p. were effective in inhibiting urinary protein excretion, elevation of serum cholesterol and creatinine contents as well as glomerular histopathological changes. In addition, berberine at 20 mg/kg/day, p.o. also inhibited urinary protein excretion throughout the experimental periods. Berberine and coptisine inhibited platelet aggregation in both in vitro and in vivo assays, and berberine inhibited the decline of renal blood flow. Although berberine inhibited an increase in thromboxane B2 formation, it increased the formation of 6-keto-prostaglandin F1 alpha in platelets and isolated glomeruli. These results indicate that the antinephritic effects of berberine and coptisine may be partly due to antiplatelet action and improved renal hemodynamics via changing prostanoid synthesis. Topics: 6-Ketoprostaglandin F1 alpha; Animals; Berberine; Cholesterol; Creatinine; Dipyridamole; Drug Evaluation, Preclinical; In Vitro Techniques; Male; Nephritis; Plant Extracts; Platelet Aggregation; Proteinuria; Rats; Rats, Sprague-Dawley; Renal Circulation; Thromboxane B2 | 1992 |
Excretion of metabolites of prostacyclin and thromboxane by rats with nephrotoxic nephritis: effects of interleukin-1.
1. To obtain direct evidence of abnormal eicosanoid biosynthesis in rats injected with anti-glomerular-basement-membrane antibodies (a-GBM), products derived from thromboxane A2 (TXA2) and prostacyclin (PGI2) were measured in 24 h urine collections before and after a-GBM. 2. Administration of a-GBM (9.5 mg) caused albuminuria, decreased creatinine clearance, increased numbers of intra-glomerular neutrophils and increased excretion of TXB2, 2,3-dinor-TXB2 (products of TXA2) and 6-oxo-PGF 1 alpha and 2,3-dinor-6-oxo-PGF 1 alpha (products of PGI2) at 24 h. 3. Interleukin-1 (IL-1 beta; 5 micrograms) alone caused an increase in PGI2 metabolite excretion but had no effect on TXA2 metabolites. It had no effect on creatinine clearance but increased numbers of glomerular neutrophils by approximately 4-5 fold compared to a-GBM. 4. Pretreatment of rats with IL-1 beta before a-GBM synergistically increased albumin excretion but only additively increased eicosanoid excretion. Numbers of intra-glomerular neutrophils and creatinine clearance were unchanged compared to IL-1 beta alone. 5. The cyclo-oxygenase inhibitor, ibuprofen (10 mgkg-1 i.p., twice daily for 4 days) inhibited both serum TXB2 production and urinary prostaglandin excretion. It also caused an almost complete attenuation of albumin excretion. Creatinine clearance and glomerular neutrophils remained unchanged after a-GBM/IL-1 beta. 6. We conclude that the 50% inhibition of thromboxane production induced by ibuprofen does not modify the fall in creatinine clearance of accumulation of neutrophils in the glomerulus caused by the a-GBM. This degree of inhibition of eicosanoid production was associated with a striking decrease in proteinuria, but this may reflect a haemodynamic rather than a disease modifying action. Topics: 6-Ketoprostaglandin F1 alpha; Animals; Creatinine; Cyclooxygenase Inhibitors; Epoprostenol; Ibuprofen; In Vitro Techniques; Interleukin-1; Kidney Glomerulus; Male; Nephritis; Neutrophils; Rats; Rats, Inbred Strains; Thromboxane B2; Thromboxanes | 1991 |
[The changes in serum TXB2 and 6-keto-PGF1 alpha in 62 cases with renal disease].
Measurement of serum thromboxane B2 (TXB2) and 6-keto-prostaglandins F1 alpha (6-keto-PGF1 alpha) was carried out in 62 patients of renal diseases. The results showed that decrease of TXB2 and 6-Keto-PGF1 alpha values and TXB2/6-Keto-PGF1 alpha ratio was correlated with the decrease of the renal function and was negatively correlated with the level of serum creatinine. The values of TXB2 and 6-Keto-PGF1 alpha were markedly elevated after hemodialysis in 19 patients. It was found that the difference between patients with and without renal hypertension was statistically significant (P less than 0.05). The results indicated that the inbalance of PG value was one of the causes of uremic hemorrhage, PG takes part in the development of renal hypertension. Topics: 6-Ketoprostaglandin F1 alpha; Adolescent; Adult; Aged; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nephritis; Renal Dialysis; Thromboxane B2 | 1989 |
The effects of a thromboxane synthase inhibitor, a prostacyclin analog and PGE1 on the nephritis of the NZB/W F1 mouse.
One hundred NZB/W F1 female mice were studied to compare the effects of a thromboxane synthase inhibitor (TSI), a stable prostacyclin analog (iloprost) and prostaglandin E1 (PGE1) in the evolution of the nephritis. At 10 weeks of age mice were randomly assigned to cohorts of 20 to receive either no treatment, vehicle control, PGE1, iloprost or TSI. Proteinuria, mortality, systemic blood pressure, renal immune complex deposition, urinary TX B2 and 6 keto PGF1 alpha levels were measured. Mice receiving PGE1 and iloprost had a significant delay in the onset of proteinuria and reduction in mortality at 40 weeks. The TSI treatment had no apparent effect on proteinuria or mortality. The amelioration of the nephritis was not associated with an alteration in immune complex deposition in survivors at 40 weeks. Although PGE1 and iloprost lessened the age related increase in urinary TX B2, increased the urinary 6 keto PGF1 alpha levels and the ratio of 6 keto PGF1 alpha to TX B2; so did the TSI. The PGE1 treated mice did experience a marked and persistent reduction in blood pressure but this was not observed in the iloprost- or the TSI-treated mice. All drugs tested reduced the age-related increase in thromboxane B2 but only the PGE1 and iloprost had a significant effect on the evolution of the nephritis. Topics: 6-Ketoprostaglandin F1 alpha; Age Factors; Alprostadil; Animals; Benzofurans; Blood Pressure; Disease Models, Animal; Epoprostenol; Female; Iloprost; Lupus Nephritis; Mice; Mice, Inbred NZB; Mice, Inbred Strains; Nephritis; Proteinuria; Thromboxane B2; Vasodilator Agents | 1987 |